Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Glibesyn vs Daonil (Glibenclamide) in Healthy Adults
NCT03855306Phase 1Completed
- Sponsor
- Genuine Research Center
- Start
- Jun 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of glibenclamide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Genuine Research Center. Primary endpoints: Maximal measured plasma concentration at 48 hours, Area under the plasma concentration-time curve from time zero to time t at 48 hours and 1 more. Started Jun 2018; status: completed.
02
Drugs
glibenclamide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03855306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03855306.